Marketed therapeutic antibodies compendium

mAbs

Volumn 4, Issue 3, 2012, Pages 413-415

  Reichert, Janice M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ADCENTRIS; ALEMTUZUMAB; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; CANAKINUMAB; CATUMAXOMAB; CENTOXIN; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NIMOTUZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

DRUG APPROVAL; DRUG MARKETING; EUROPE; HUMAN; PHYSICIAN; REVIEW; UNITED STATES;

EID: 84860896956     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.19931     Document Type: Review

References (16)

1. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. March 2012. www.ema.europa.eu/docs/en-GB/document-library/Report/2012/03/WC500123528.pdf
2. Shulman M, Wilde CD, Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 276:269-70; PMID:714156; http://dx.doi.org/10.1038/276269a0.
3. Clark MR, Milstein C. Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines. Somatic Cell Genet 1981; 7:657- 66; PMID:7323946; http://dx.doi.org/10.1007/BF01538755.
4. Mahmud N, Klipa D, Ahsan N. Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs 2010; 2:148-56; PMID:20150766; http://dx.doi.org/10.4161/mabs.2.2.11159.
5. Janssen-Cilag. Orthoclone® OKT3 muromonab-CD3-Worldwide discontinuation [press release], January 4, 2010. www.cochrane-renal.org/docs/ Newsletter-October-2010.pdf
6. Rosenberg LT. Delaying approval of a critical drug: safety, efficacy, economics, compassion. J Med Humanit 1994; 15:243-50; PMID:11645897; http://dx.doi.org/10.1007/BF02273711.
7. Marks L. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin. MAbs 2012; 4; In press.
8. Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360:671-7; PMID:12241873; http://dx.doi.org/10.1016/S0140-6736(02)09836-7.
9. European Medicines Agency public statement on Zenapax (daclizumab): withdrawal of the marketing application in the Europe Union, January 16, 2009. www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/11/ WC500011995.pdf
10. Roche letter to healthcare professionals, September 2009. www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf
11. United States Food and Drug Administration. Pfizer voluntarily withdraws cancer treatment Mylotarg from USmarket, June 21, 2010. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm216448.htm
12. European Medicines Agency public statement on Raptiva (efalizumab): withdrawal of the marketing application in the Europe Union, August 3, 2009. www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/11/ WC500009129.pdf
13. United States Food and Drug Administration statement on the voluntary withdrawal of Raptiva from the USmarket, April 8, 2009. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2009/ucm149561.htm
14. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009; 1:41-8; PMID:20046573; http://dx.doi.org/10.4161/ mabs.1.1.7509.
15. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28:1591-8; PMID:20177026; http://dx.doi.org/10. 1200/JCO.2009.25.3575.
16. Reichert JM. Which are the antibodies to watch in 2012? MAbs 2012; 4:1-3; PMID:22327425; http://dx.doi.org/10.4161/mabs.4.1.18719.